Clinical practice and implications of recent diabetes trials

Current Opinion in Cardiology

Volumn 26, Issue 4, 2011, Pages 288-293

  Webster, Mark W I ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

aspirin; diabetes; dyslipidemia; hypertension; revascularization; statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMLODIPINE; BENAZEPRIL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; STATIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS;

EID: 79958817945     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328347b139     Document Type: Review

References (31)

1. Kotseva K, Wood D, De Backer G, et al., for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373:929-940.
2. Franks PW, Hanson RL, Knowler WC, et al. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010; 362:485-493.
3. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010; 375:2215-2222. A comprehensive analysis of relationship between diabetes and vascular disease.
4. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829-841.
5. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818-828. Longer-term follow-up on the key randomized trial showing increased mortality with aggressive glucose lowering using current established drugs.
6. Zoungas S, Patel A, Chalmers J, et al., for the ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410-1418.
7. Riddle MC, Ambrosius WT, et al. Epidemiologic relationships between HbA1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33:983-990.
8. Ismail-Beigi F, Craven T, Banerji MA, et al., for the ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419-430.
9. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
10. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type2 diabetes: a retrospective cohort study. Lancet 2010; 375:481-489.
11. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800-811.
12. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
13. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170:1892-1899. Registry study providing support for using metformin in higher-risk diabetic patients.
14. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121:1868-1877. Good summary of current knowledge on the cardiovascular safety or otherwise of glitazones.
15. Gerstein HC, Ratner RE, Cannon CP, and the APPROACH study group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease. The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121:1176-1187.
16. Nissen SE, Nicholls SJ, Wolski K, et al., for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomised controlled trial. JAMA 2008; 299:1561-1573.
17. Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high- density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (pioglitazone effect on regression of intravascular sonographic coronary obstruction prospective evaluation) study. J Am Coll Cardiol 2011; 57:153-159.
18. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
19. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55:2878-2886. A summary of current evidence on aspirin for primary prevention of vascular events in diabetic patients.
20. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585. A key randomized trial showing no incremental benefit with lowering SBP below 130mmHg in diabetic patients.
21. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
22. Weber MA, Bakris GL, Jamerson K, et al., for the ACCOMPLISH investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56:77-85.
23. Cholesterol treatment trialists' (CTT) Collaborators. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125.
24. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875-1884.
25. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574. Another important ACCORD study showing no evidence for routinely adding a fibrate to a statin in those with diabetes.
26. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-742.
27. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503-2515. An important, well designed trial comparing revascularization with medical treatment in diabetic patients with stable coronary disease.
28. Brooks MM, Chung SC, Helmy T, et al. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 diabetes trial. Circulation 2010; 122:1690-1699.
29. Serruys PW, Morice MC, Kappetein AP, et al., for the SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961-972. The first large, randomized trial comparing PCI using drug-eluting stents with CABG in patients with multivessel and/or left main coronary disease.
30. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease. Comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010; 55:1067-1075.
31. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55:432-440.